Compare Direxion Daily TSLA Bull 2X Shares (TSLL) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Direxion Daily TSLA Bull 2X Shares vs Travere Therapeutics Inc. Common Stock — how do they compare? Direxion Daily TSLA Bull 2X Shares trades at $9.24 (market cap $3.84B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Travere Therapeutics Inc. Common Stock is the larger of the two by market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, Direxion Daily TSLA Bull 2X Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Direxion Daily TSLA Bull 2X Shares for 15 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| TSLL | TVTX | |
|---|---|---|
Market Cap | $3.84B | $4.88B |
Volume | 36,217,346 | 1,668,577 |
Sector | Leveraged / Inverse | Health |
52-Week High | $23.03 | $67.52 |
52-Week Low | $6.74 | $26.79 |
Typical Hold Time | 15 Days | 0 Days |
Enterprise Value | — | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TSLL, the Direxion Daily TSLA Bull 2X Shares ETF, trades at $10.00, down 1.48% on the day, reflecting amplified exposure to Tesla's volatility. The technical outlook is mixed with a neutral overall signal, while recent news highlights its sensitivity to Tesla-specific catalysts like the Cybercab event. Financial ratios are not applicable as this is a leveraged ETF tracking Tesla's daily performance.
The outlook for TSLL is directly tied to Tesla's stock momentum, offering potential for magnified gains but carrying high risk from daily rebalancing and volatility decay. Investors face significant downside risk if Tesla trends lower, making it suitable only for short-term, risk-tolerant traders monitoring Tesla's news flow.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Direxion Daily TSLA Bull 2X Shares
TSLL provides 200% of the daily performance of Tesla, Inc. (TSLA). It uses swaps and financial derivatives to achieve its 2x leverage, making it a high-volatility tool for tactical trading rather than long-term investment due to daily resets.
Read more on TSLL →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
